Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

High-Quality Glaxo Could Still Have Something Left

Back in the summer of 2012, I thought investors would do well to give GlaxoSmithKline (NYSE:GSK) a pass, as the investment community was down on the company's near-term earnings momentum and worried about pricing developments in Europe. As it happens, Glaxo was one of the weakest Big Pharma stocks since then.

That was then, and this is now. Although revenue is likely to remain pressured next year and a billion-pound cost-cutting program is a long-term contributor at best, Glaxo could be getting more interesting. The company should have multiple high-potential product launches this year and data on multiple high-risk/high-reward Phase programs. Pricing pressure and threats to COPD franchise are both risks (as is Wall Street disinterest with sluggish...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details